Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Enlight Renewable Energy Q3 2025 Earnings Call - Robust Growth Driven by U.S. Projects and Energy Storage Expansion
Enlight Renewable Energy reported a resounding Q3 2025 performance, fueled by a 46% surge in revenue to $165 million and a 23% increase in adjusted EBITDA to $112 million. This growth was propelled by...
- Enlight posted a 46% year-over-year revenue increase to $165 million in Q3 2025, driven by new operational projects in the U.S., Israel, and Europe.
- Adjusted EBITDA grew 23% to $112 million, with net income rising 33% to $32 million, underpinned by new projects and tax benefits.
- The company raised its full-year 2025 guidance, now expecting revenues between $555M and $565M and adjusted EBITDA between $405M and $415M.
- +12 more takeaways
Humacyte Q3 2025 Earnings Call - Commercial Traction Grows as Symvess Advances in Trauma and Dialysis Access
Humacyte reported robust progress in the third quarter of 2025, focusing on the commercial launch of Symvess and advancement in their bioengineered vessel programs. The company secured 25 hospital or ...
- Humacyte’s Symvess commercial launch gained significant momentum with 25 hospital or health system VAC approvals covering 92 hospitals eligible to purchase.
- Symvess product sales jumped to $703,000 in Q3, a seven-fold increase over the prior quarter’s $100,000.
- Publications demonstrate Symvess’s efficacy in treating hospital-acquired vascular injuries, wartime combat injuries, and showing comparable outcomes to autologous vein grafts.
- +12 more takeaways
Caesarstone Q3 2025 Earnings Call - Transformation Accelerates with Full Outsourcing and $85M+ Cost Savings
Caesarstone's Q3 2025 results reveal a company deep in transformation, shifting fully to outsourced production outside its Bar-Lev facility, aiming to cut costs by over $85 million since 2023. Revenue...
- Caesarstone is closing its Bar-Lev manufacturing facility to fully outsource production except porcelain.
- Outsourcing is expected to generate $22 million in annual cash savings starting in 2026, with total savings since 2023 exceeding $85 million.
- Q3 2025 revenue declined 5.7% on a constant currency basis to $102.1 million, impacted mainly by softer demand and heightened competition globally.
- +7 more takeaways
Regis Corporation Q1 2026 Earnings Call - Progress in Supercuts Transformation and Company-Owned Salon Integration Drive Growth
Regis Corporation reported a modest 0.9% increase in consolidated same-store sales for Q1 fiscal 2026, aided by strategic pricing, operational efficiency, and the integration of 281 company-owned salo...
- Consolidated same-store sales rose 0.9% in Q1 fiscal 2026, reflecting pricing actions and salon-level execution improvements.
- Adjusted EBITDA increased 4.3% year-over-year to $8 million, driven by company-owned salon contributions and cost discipline.
- Positive operating cash flow of $2.3 million was achieved, marking four consecutive quarters of positive cash generation.
- +11 more takeaways
European Wax Center Q3 2025 Earnings Call - Building Foundations with Stable Core and Data-Driven Transformation
European Wax Center reported steady progress in Q3 2025 with system-wide sales reaching $238.2 million and a slight 20 basis points increase in same-store sales, reflecting a stable core customer base...
- Q3 system-wide sales were $238.2 million, down 0.8% year-over-year mainly due to closed centers.
- Same-store sales grew modestly by 20 basis points, signaling a stable core business.
- Adjusted EBITDA rose 9.6% to $20.2 million, with margin improvement to 37.2%.
- +13 more takeaways
Sanara MedTech Q3 2025 Earnings Call - Strategic Shift to Core Surgical Business Fuels 22% Revenue Growth
Sanara MedTech’s third quarter 2025 earnings report marks a pivotal strategic shift, as the newly appointed CEO Seth Yon confirms the discontinuation of the Tissue Health Plus (THP) segment after an e...
- Seth Yon appointed Sanara’s President and CEO as of September 15, bringing seven years of internal commercial leadership experience to the top role.
- The company announced discontinuation of Tissue Health Plus (THP) operations after failing to find a partner to scale or monetize the business, signaling a strategic retreat from this segment.
- THP cash investment in H2 2025 expected between $5.5 million and $6.5 million, with no material cash spend anticipated post-2025.
- +10 more takeaways
Acurx Pharmaceuticals 3Q 2025 Earnings Call - Progress on Microbiome-Sparing Antibiotic Class and NASDAQ Compliance Achieved
Acurx Pharmaceuticals reported financial results for Q3 2025 while highlighting key operational milestones including a 1-for-20 reverse stock split that restored NASDAQ listing compliance. The company...
- Completed a 1-for-20 reverse stock split in August 2025, regaining NASDAQ minimum bid price compliance and meeting stockholder equity requirements to maintain listing.
- Received new Australian patent approval for DNA polymerase 3C inhibitors, adding to existing US, Israeli, Japanese, Indian patents and strengthening global IP coverage.
- Raised approximately $1.7 million from an equity line of credit during Q3 and an additional $1.4 million post-quarter through warrant exercises, ending with $5.9 million cash plus recent proceeds.
- +9 more takeaways
Acumen Pharmaceuticals Q3 2025 Earnings Call - Advancing Phase 2 Alzheimer's Trial with Strategic BBB Tech Collaboration
Acumen Pharmaceuticals reported solid progress in its phase two ALTITUDE-AD trial targeting synaptotoxic A-beta oligomers in Alzheimer's disease, with first participants moving into an open-label exte...
- ALTITUDE-AD phase two trial for sabirnetug, targeting toxic A-beta oligomers in Alzheimer's, is progressing steadily with 542 participants enrolled.
- First patients are entering the open-label extension (OLE), receiving 35 mg/kg sabirnetug every 4 weeks for up to 52 weeks to collect long-term safety and efficacy data.
- Top-line results for ALTITUDE-AD, including efficacy and safety, are expected in late 2026.
- +7 more takeaways
Katapult Holdings Q3 2025 Earnings Call - Accelerated Application Growth Drives Expanding Customer Base and Positive Adjusted EBITDA
Katapult Holdings reported a robust Q3 2025, marked by a 76% growth in applications year-to-date and 47% growth in Q3 alone, fueling a 30% expansion in its total customer base. This accelerated top-of...
- Katapult grew total applications by 76% in the first nine months of 2025, with an 80% increase in Q3 alone, indicating strong top-of-funnel activity.
- The total customer base expanded over 30% in Q3, fueled by a near 47% growth in unique new customers, marking four consecutive quarters of accelerating customer growth.
- Monthly active users of the Katapult app increased nearly 49% year-over-year in Q3, reflecting enhanced consumer engagement and app-driven marketplace growth.
- +11 more takeaways
Yatra Fiscal Q2 2026 Earnings Call - Surge in Revenue and Profitability Driven by Corporate Travel Expansion
Yatra reported a standout second quarter in fiscal 2026, with revenues climbing nearly 50% year over year to $39.5 million and profits turning positive to $1.1 million from a previous loss. This perfo...
- Yatra’s Q2 fiscal 2026 revenue grew 48.5% year over year to INR 3,508 million ($39.5 million).
- Adjusted EBITDA surged 218% year over year to INR 212 million ($2.4 million).
- Profit after tax increased to INR 98.8 million ($1.1 million) versus a loss in prior year period.
- +9 more takeaways